Biotricity Inc. 2026年季度报告

Form 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended December 31, 2025☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ______________ to_______________ Commission file number: 001-40761 BIOTRICITY INC. (Exact name of registrant as specified in its charter) Nevada(State or other jurisdiction ofincorporation or organization) 30-0983531(I.R.S. EmployerIdentification No.) 203 Redwood Shores Parkway, Suite 600Redwood City, California 94065(Address of principal executive offices) (800) 590-4155(Registrant’s Telephone Number, Including Area Code) Indicate by check whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting Large accelerated filer☐Non-accelerated filer☒ Accelerated filer☐Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ Securities registered pursuant to Section 12(b) of the Act: None Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 28,436,643shares of Common Stock, $0.001 par value, at February 11, 2026. As at that same date, the Company also has 160,672 Exchangeable PART 1 FINANCIAL INFORMATION Condensed Consolidated Interim Balance Sheets at December 31, 2025 (unaudited) and March 31, 2025 (audited)4Condensed Consolidated Interim Statements of Operations and Comprehensive Loss for the three and nine months endedDecember 31, 2025 and 2024 (unaudited)5Condensed Consolidated Interim Statements of Mezzanine Equity and Stockholders’ Deficiency for the three and nine monthsended December 31, 2025 and 2024 (unaudited)6Condensed Consolidated Interim Statements of Cash Flows for the nine months ended December 31, 2025 and 2024(unaudited)8Notes to the Condensed Consolidated Interim Financial Statements93 BIOTRICITY INC.NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 1. NATURE OF OPERATIONS Biotricity Inc. (the “Company” or “Biotricity”) was incorporated under the laws of the State of Nevada on August 29, 2012. iMedicalInnovations Inc. (“iMedical”) was incorporated on July 3, 2014 under the laws of the Province of Ontario, Canada and became a The Company (directly and through its subsidiary) is engaged in research and development activities within the remote monitoringsegment of preventative care. It is focused on a realizable healthcare business model that has an existing market and commercialization 2. BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with accountingprinciples generally accepted in the United States (“US GAAP”) for interim financial information and the Securities and ExchangeCommission (“SEC”) instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, they do not include all of the The accompanying unaudited condensed consolidated interim financial statements are expressed in United States dollars (“USD”). Inthe opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation offinancial position and results of operations for the interim periods presented have been reflected herein. Operating results for the The unaudited condensed consolidated interim financial statements include the accounts of the Company and its wholly-ownedsubsidiary. Significant intercompany accounts and transactions have been eliminated. Reclassifications Certain amounts presented in the prior year period have been reclassified to confirm to current period consolidated interim financialstatement presentation. Going Concern, Liquidity and Basis of Presentation The accompanying condensed consolidated interim financial statements have been prepared assuming that the Company will continueas a going concern. The Company